Published in Clin Exp Immunol on June 01, 2001
Murine models of systemic lupus erythematosus. Adv Immunol (1985) 9.79
A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods (1983) 6.71
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med (2000) 4.99
Selective induction of DNA synthesis in T and B lymphocytes. Cell Immunol (1972) 4.94
B lymphocyte differentiation induced by lipopolysaccharide. I. Generation of cells synthesizing four major immunoglobulin classes. J Immunol (1975) 3.62
Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med (1981) 3.27
Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell (1996) 2.31
Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med (2000) 1.99
Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis (1998) 1.73
Mechanism of action of mycophenolate mofetil. Ther Drug Monit (1995) 1.42
In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc (1991) 1.00
Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res (1990) 1.00
Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosis. Endocrinology (1998) 1.00
Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc (1991) 0.98
Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol (1998) 0.98
Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int (1997) 0.98
Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol (1999) 0.93
Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol (1999) 0.92
Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice. Cell Immunol (1999) 0.92
Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol (1999) 0.88
Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation (1999) 0.87
Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus (1999) 0.87
Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant (1999) 0.86
Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis (1998) 0.86
Simple and sensitive high-performance liquid chromatographic. J Chromatogr B Biomed Sci Appl (2000) 0.86
Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens (1999) 0.83
Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol (1998) 0.81
Atypical signaling defects prevent IL-2 gene expression in lpr/lpr CD4-CD8- cells. J Biomed Sci (1998) 0.81
Frequency and phenotypic feature of autoantibody-producing cell precursors in the preclinical stage of murine lupus. Immunology (1990) 0.77
Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum (1989) 1.95
Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum (1990) 1.75
Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J Endocrinol (2002) 1.33
Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus (2000) 1.26
Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology (2001) 1.25
Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis (2003) 1.22
The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovariectomized mice. Am J Physiol Endocrinol Metab (2008) 1.22
Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol (1992) 1.19
Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J (2009) 1.14
Impaired cutaneous delayed-type hypersensitivity in autoimmune MRL lpr/lpr mice. Int Arch Allergy Appl Immunol (1986) 1.13
Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. Br J Rheumatol (1989) 1.03
Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cell Immunol (1994) 1.02
Neutrophil mediated inflammatory response in murine lupus. Autoimmunity (1993) 1.00
Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol (2002) 0.98
Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford) (2007) 0.98
Influence of oestrogen receptor alpha and beta on the immune system in aged female mice. Immunology (2003) 0.97
Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. J Endocrinol (2001) 0.96
Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology (2003) 0.94
Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss. Bone (2005) 0.94
Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol (1999) 0.92
Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis. Clin Exp Immunol (1999) 0.92
Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) (2008) 0.92
Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice. Cell Immunol (1999) 0.92
T lymphocytes are not the target for estradiol-mediated suppression of DTH in reconstituted female severe combined immunodeficient (SCID) mice. Clin Exp Immunol (1998) 0.91
Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease. Agents Actions (1990) 0.89
Estrogenic agonism and antagonism of the soy isoflavone genistein in uterus, bone and lymphopoiesis in mice. APMIS (2005) 0.87
Identification of target cells for the genomic effects of estrogens in bone. Endocrinology (2007) 0.86
Expression of the mucosal lymphocyte integrin alphaEbeta7 and its ligand E-cadherin in salivary glands of patients with Sjögren's syndrome. Scand J Rheumatol (1998) 0.84
Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol (2008) 0.84
Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell Immunol (2000) 0.83
Differential immunological aberrations in patients with primary and secondary Sjögren's syndrome. Scand J Immunol (1997) 0.82
The gut as an inductive site for synovial and extra-articular immune responses in rheumatoid arthritis. Ann Rheum Dis (1994) 0.82
Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis. Clin Exp Immunol (2011) 0.81
Estren-mediated inhibition of T lymphopoiesis is estrogen receptor-independent whereas its suppression of T cell-mediated inflammation is estrogen receptor-dependent. Clin Exp Immunol (2005) 0.81
Health-related quality of life in systemic lupus erythematosus and its association with disease and work disability. Scand J Rheumatol (2010) 0.81
The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand J Immunol (2008) 0.79
Cutaneous delayed type hypersensitivity in SCID mice adoptively transferred with lymphocytes is B cell independent and H-2 restricted. Scand J Immunol (1997) 0.79
Genetic variants in CARD8 but not in NLRP3 are associated with ankylosing spondylitis. Scand J Rheumatol (2013) 0.79
Intra-articular immunization induces strong systemic immune response in humans. Clin Exp Immunol (1990) 0.79
Decreased serum levels of TGF-β1 are associated with renal damage in female patients with systemic lupus erythematosus. Lupus (2011) 0.79
Frequency and phenotypic feature of autoantibody-producing cell precursors in the preclinical stage of murine lupus. Immunology (1990) 0.77
Peripheral denervation suppresses the late phase of delayed-type hypersensitivity. Int Arch Allergy Appl Immunol (1991) 0.77
17Beta-estradiol expands IgA-producing B cells in mice deficient for the mu chain. Scand J Immunol (2007) 0.76
Action of dexamethasone in the suppression of delayed-type hypersensitivity in reconstituted SCID mice. Inflamm Res (2000) 0.76
Enhanced natural but diminished antibody-mediated cytotoxicity in the lungs of MRLlpr/lpr mice. Clin Exp Immunol (1996) 0.76